Foundayo vs Wegovy: Evidence and Administration (2026)
The FDA approved Foundayo (orforglipron) on April 1, 2026 as a once-daily oral option for chronic weight management in eligible adults. Wegovy is once-weekly injectable semaglutide. ATTAIN-1 and STEP 1 were separate studies with different designs, so their results are not head-to-head evidence.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
In ATTAIN-1, orforglipron 36 mg was studied for 72 weeks in adults without diabetes; mean body-weight change was −11.2% by the treatment-regimen estimand and −12.4% by the efficacy estimand. In STEP 1, semaglutide 2.4 mg produced −14.9% mean weight loss at 68 weeks.
The different trial populations, durations, and analysis plans mean the figures cannot establish comparative efficacy. This page does not verify Foundayo provider availability, cash prices, or insurance coverage; a licensed prescriber can discuss treatment options in context.
What the Studies Actually Show
This comparison uses separate pivotal trials: ATTAIN-1, NEJM 2025 for orforglipron and STEP 1, NEJM 2021 for semaglutide. No direct head-to-head trial has been published.
| Endpoint | Foundayo (orforglipron) | Wegovy injection (semaglutide) |
|---|---|---|
| Mean body-weight change (separate pivotal trials)1,2 | −11.2% (ATTAIN-1, 72 weeks, 36 mg; treatment-regimen estimand) Different trials, populations, durations, and analysis plans; this is not a head-to-head comparison. | −14.9% (STEP 1, 68 weeks, 2.4 mg) |
| Administration | Once-daily oral pill; FDA label permits administration with or without food | Once-weekly subcutaneous injection |
| Cardiovascular outcomes evidence3 | ATTAIN-1 was not a cardiovascular-outcomes trial | SELECT trial: 20% relative risk reduction in MACE in adults with established cardiovascular disease and overweight or obesity |
| FDA approval for weight management | April 1, 2026 | June 2021 |
Who Should Choose Foundayo vs Wegovy
Choose Foundayo if…
- You want a daily pill and the lowest brand-name starting price ($149).
- You're comparing pills: Foundayo and the Wegovy pill cost about the same, so the choice comes down to the clinician's view and how you tolerate each.
Choose Wegovy if…
- You prefer a once-weekly injection, or want the drug with established cardiovascular-outcome data.
- You want a pill on a familiar molecule: the Wegovy pill (semaglutide) is $149 to $299 a month.
Monthly Cost Compared
| Foundayo (pill) | Wegovy (pen / pill) | |
|---|---|---|
| Start | $149 a month | Pen $199 for the first two fills; pill $149 |
| Maintenance | $299 a month | Pen $349; pill $299 |
| Approximate first year | $3,188 | Pen $3,888; pill $3,338 |
Self-pay prices from NovoCare and LillyDirect, checked October 21, 2026, assuming one month at each dose step. With commercial insurance that covers the drug, manufacturer savings programs can bring the cost to as little as $25 a month. A prescriber decides the dose schedule.
The Verdict
Foundayo is an oral option and Wegovy is an injection, but their separate trial results are not direct comparative evidence. A licensed prescriber should individualize the choice using approved use, medical history, risks, preferences, and access.
Frequently Asked Questions
Is Foundayo better than Wegovy?
No direct head-to-head trial has established that either medicine is better. ATTAIN-1 reported −11.2% mean body-weight change at 72 weeks with orforglipron 36 mg by the treatment-regimen estimand (−12.4% by the efficacy estimand); STEP 1 reported −14.9% at 68 weeks with semaglutide 2.4 mg. The separate results are not directly comparable.
Can I take Foundayo instead of Wegovy?
Switching between GLP-1 medicines is a clinical decision. A licensed prescriber should consider approved use, medical history, contraindications, other medicines, response, tolerability, and access before recommending a change.
Are Foundayo and Wegovy prices directly comparable?
This page does not verify Foundayo cash prices, provider availability, savings offers, or insurance coverage. Confirm current product, pharmacy, total cost, and coverage details directly with a licensed prescriber, dispensing pharmacy, and insurer.
- ATTAIN-1 — NEJM 2025 · Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025. ATTAIN-1, 72 weeks.
- STEP 1 — NEJM 2021 · Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002.
- SELECT — NEJM 2023 · Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221–2232.
RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.